Nobilis Health Reports Third Quarter 2016 Financial Results
Reiterates Full Year 2016 Guidance for Revenue and Adjusted EBITDA(1)
Tweet
Share
E-mailHOUSTON, TX -- (Marketwired) -- 11/07/16 -- Nobilis Health Corp. (NYSE MKT: HLTH) (TSX: NHC) ("Nobilis" or the "Company") today announced financial results for the third quarter ended September 30, 2016. All financial results are expressed in U.S. dollars.
Third Quarter Highlights
- Revenues Increase 34.7% to $70.7 million
- Net Loss of $2.8 million, Compared to Prior Period Net Income of $10.9 million
- Adjusted EBITDA(1) of $4.3 million, Compared to Prior Period of $5.3 million
- Cash Increases 25.2% to $19.6 million Compared to Year End 2015
- $4.7 million in Additional Incremental Sales, Marketing and Ancillary Expenses
- Reiterates Full Year 2016 Guidance for Revenue and Adjusted EBITDA(1)
"Nobilis made significant progress in the third quarter both financially and operationally. We continued our strong revenue performance for the year, realizing organic revenue growth as well as growth at the hospitals acquired in 2015," said Harry Fleming, Chief Executive Officer of Nobilis.
"Our new credit facility, announced in October, significantly strengthens our balance sheet and substantially increases our financial resources, giving us the flexibility we need to help us achieve our acquisition goals. We also made significant progress integrating recently acquired facilities, including the five clinics and four surgery centers acquired as part of our acquisition of 'Arizona Vein and Vascular Clinics' and our new Galveston-area surgery center. We remain on track to deliver the full year 2016 financial guidance we previously provided," continued Harry Fleming, Chief Executive Officer of Nobilis.
Kenneth Efird, President, Nobilis said, "Our third quarter Adjusted EBITDA(1) of $4.3 million was impacted by expenses for direct-to-consumer marketing, physician marketing, physician recruitment, and ancillary service line expansion. We deployed in the third quarter a portion of direct-to-consumer marketing expenses budgeted for the fourth quarter. This marketing expense acceleration allowed us to avoid higher fourth quarter premiums for digital online, social media and direct response television expenses, resulting from the U.S. presidential election."
"We also increased our physician marketing expense with the recruitment of several new physicians. Finally, we expanded our anesthesia footprint and launched a new laboratory division. These efforts support our strategic growth initiatives and the marketing of our specialty services to hospitals acquired in 2015. These additional third quarter expenses will drive cases in the fourth quarter, our most profitable quarter," continued Kenneth Efird, President of Nobilis.
Third Quarter 2016 Financial Results Total revenue for the third quarter of 2016 increased to $70.7 million, a 34.7% increase over the same period the prior year. Total case volume increased by 679 cases, or 15.4%, to 5,097 cases in the third quarter of 2016, as compared to the same period the prior year. Revenue per case increased to $13,256 in the third quarter of 2016, as compared to $11,392 in the same period the prior year, reflecting the impact of a higher acuity case mix performed in hospitals. The increase in total revenue and total case volume in the third quarter compared to the same quarter the prior year was primarily organic growth.
Net loss attributable to Nobilis for the third quarter of 2016 was $2.8 million, or $0.04 per basic and fully diluted share, as compared to a prior period net income attributable to Nobilis of $10.9 million, or $0.15 and $0.14 per basic and fully share, respectively. Net income in the third quarter of 2015 included a $4.4 million bargain purchase gain and a $6.4 million change in fair value of warrants and stock options.
Adjusted EBITDA(1) for the third quarter of 2016, which adds back certain non-cash and non-recurring expenses, was $4.3 million, a decrease of 18.3% over Adjusted EBITDA(1) of $5.3 million for the same period the prior year.
Total cash was $19.6 million, accounts receivable was $86.2 million and total debt was $23.8 million as of September 30, 2016, compared to $15.7 million, $92.6 million and $22.7 million, respectively, at December 31, 2015.
As of September 30, 2016, the Company owned and/or managed four acute care surgical hospitals and five ambulatory surgical centers, and had affiliations with an additional 36 facilities.
Nine Months Ended 2016 Financial Results Total revenue for the first nine months of 2016 increased to $183.8 million, a 32.1% increase over the same period the prior year. Total case volume for the first nine months of 2016 increased by 1,385 cases, or 11.0%, to 13,934 in the first nine months of 2016, compared to the same period the prior year. Revenue per case increased to $13,193 for the first nine months of 2016, as compared to $11,093 in the same period the prior year, reflecting the impact of a higher acuity case mix from the purchase of three new hospitals in 2015. The increase in total revenue and total case volume for the first nine months of 2016 compared to the same period the prior year was due primarily to the acquisitions of three hospitals in 2015.
Net loss attributable to Nobilis for the first nine months of 2016 was $2.9 million, or $0.04 per basic and fully diluted share, as compared to net income attributable to Nobilis of $6.0 million, or $0.09 per basic and fully diluted share, in the same period the prior year.
Adjusted EBITDA(1) for the first nine months of 2016, which adds back certain non-cash and non-recurring expenses, was $13.2 million, a decrease of 20.5% compared to Adjusted EBITDA(1) of $16.6 million for the same period the prior year.
Full Year 2016 Guidance For full year 2016, Nobilis is reiterating the guidance previously provided on October 28, 2016 when we completed the acquisition of Arizona Vascular Clinics. Full year 2016 total revenues are expected to be $281.0 million, and Adjusted EBITDA(1) is expected to be $53.0 million.
Conference Call Information Nobilis will host a conference call on November 7, 2016 at 8:00 a.m. CDT (9:00 a.m. EDT) to discuss its financial results for the third quarter of 2016. To participate in the conference call, please dial (877) 201-0168 in the U.S. and Canada, and +1 (647) 788-4901 internationally. Please enter conference ID 13721251. There will be a livestream of the conference call available at: http://investors.nobilishealth.com/investors/events-and-presentations/.
About Nobilis Health Corp. Nobilis (www.NobilisHealth.com) is a full-service healthcare development and management company which currently owns or manages fourteen surgical facilities and six clinics, partners with thirty-six additional facilities throughout the country, and markets seven independent brands. Deploying a unique patient acquisition strategy driven by direct-to-consumer marketing, Nobilis is focused on a specified set of procedures that are performed at our centers by local physicians.
Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to our ability to successfully maintain effective internal controls over financial reporting; our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; adverse developments affecting the medical practices of our physician limited partners; our ability to maintain favorable relations with our physician limited partners; our ability to grow revenues by increasing case and procedure volume while maintaining profitability at the Nobilis Facilities; failure to timely or accurately bill for services; our ability to compete for physician partners, patients and strategic relationships; the risk of changes in patient volume and patient mix; the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and the risk of potential decreases in our reimbursement rates. The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect us in an adverse manner.
We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to any mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 15, 2016, as updated by other filings with the Securities and Exchange Commission.
NOBILIS HEALTH CORP.
CONSOLIDATED BALANCE SHEETS
September 30, 2016 AND December 31, 2015
(In thousands, except share amounts)
(unaudited)
September 30, December 31,
2016 2015
---------------- ----------------
Assets
Current Assets:
Cash $ 19,614 $ 15,666
Trade accounts receivable, net of
allowance of $2,144 at September 30,
2016 and $5,165 at December 31, 2015 86,170 92,569
Medical supplies 4,321 4,493
Prepaid expenses and other current
assets 3,727 2,789
---------------- ----------------
Total current assets 113,832 115,517
Property and equipment, net 34,638 35,303
Intangible assets, net 18,268 19,619
Goodwill 44,833 44,833
Deferred tax asset 27,470 25,035
Other long-term assets 1,942 1,720
---------------- ----------------
Total Assets $ 240,983 $ 242,027
================ ================
Liabilities and Shareholders' Equity
Current Liabilities:
Trade accounts payable $ 19,702 $ 23,381
Accrued expenses 20,661 16,648
Current portion of capital leases 3,484 5,193
Current portion of long-term debt 1,006 1,243
Current portion of warrant and stock
option derivative liabilities 380 332
Other current liabilities 6,802 5,025
---------------- ----------------
Total current liabilities 52,035 51,822
Lines of credit 8,135 3,000
Long-term capital leases, net of current
portion 12,711 13,654
Long-term debt, net of current portion 22,826 21,469
Warrant and stock option derivative
liabilities, net of current portion 1,537 2,619
Other long-term liabilities 3,523 3,386
---------------- ----------------
Total liabilities 100,767 95,950
---------------- ----------------
Commitments and Contingencies
Contingently redeemable noncontrolling
interest 10,567 12,225
Shareholders' Equity:
Common shares, no par value, unlimited
shares authorized, 76,855,014 and
73,675,979 shares issued and
outstanding, respectively -- --
Additional paid in capital 218,724 211,827
Accumulated deficit (88,410) (85,491)
---------------- ----------------
Total shareholders' equity attributable
to Nobilis Health Corp. 130,314 126,336
Noncontrolling interests (665) 7,516
---------------- ----------------
Total shareholders' equity 129,649 133,852
---------------- ----------------
Total Liabilities and Shareholders'
Equity $ 240,983 $ 242,027
================ ================
NOBILIS HEALTH CORP
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except earnings per share)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2016 2015 2016 2015
----------- ----------- ----------- -----------
Revenues:
Patient and net
professional fees $ 65,666 $ 46,237 $ 167,199 $ 126,661
Contracted marketing
revenues 2,604 4,410 10,754 8,059
Factoring revenues 2,413 1,836 5,874 4,481
----------- ----------- ----------- -----------
Total revenues 70,683 52,483 183,827 139,201
Operating expenses:
Salaries and benefits 13,209 10,255 38,377 26,927
Drugs and supplies 15,473 8,405 39,670 22,265
General and
administrative 33,195 21,025 85,678 54,625
Bad debt expense -- 929 -- 1,129
Depreciation and
amortization 1,952 1,522 6,462 3,114
----------- ----------- ----------- -----------
Facility operating
expenses 63,829 42,136 170,187 108,060
Corporate expenses:
Salaries and benefits 1,765 1,540 5,077 3,532
General and
administrative 4,576 5,192 14,984 17,707
Legal expenses 1,535 521 4,110 1,733
Depreciation 79 43 209 99
----------- ----------- ----------- -----------
Total corporate costs 7,955 7,296 24,380 23,071
----------- ----------- ----------- -----------
(Loss) income from
operations (1,101) 3,051 (10,740) 8,070
Other expense (income) :
Change in fair value
of warrant and stock
option derivative
liabilities 133 (6,381) (1,566) (4,677)
Interest expense 744 322 2,115 1,106
Bargain purchase gain -- (4,358) -- (4,358)
Other income, net (198) (106) (3,011) (1,518)
----------- ----------- ----------- -----------
Total other expense
(income) 679 (10,523) (2,462) (9,447)
(Loss) income before
income taxes and
noncontrolling
interests (1,780) 13,574 (8,278) 17,517
----------- ----------- ----------- -----------
Income tax expense
(benefit) 483 256 (1,766) 862
----------- ----------- ----------- -----------
Net (loss) income (2,263) 13,318 (6,512) 16,655
=========== =========== =========== ===========
Net income (loss)
attributable to
noncontrolling
interests 496 2,375 (3,594) 10,617
----------- ----------- ----------- -----------
Net (loss) income
attributable to Nobilis
Health Corp. $ (2,759) $ 10,943 $ (2,918) $ 6,038
=========== =========== =========== ===========
Net (loss) income per
basic common share $ (0.04) $ 0.15 $ (0.04) $ 0.09
=========== =========== =========== ===========
Net (loss) income per
fully diluted common
share $ (0.04) $ 0.14 $ (0.04) $ 0.08
=========== =========== =========== ===========
Weighted average shares
outstanding (basic) 76,774,967 70,935,587 76,114,538 65,310,610
=========== =========== =========== ===========
Weighted average shares
outstanding (fully
diluted) 76,774,967 77,656,264 76,114,538 75,067,623
=========== =========== =========== ===========
NOBILIS HEALTH CORP.
RECONCILIATION ON NON-GAAP FINANCIAL MEASURES
(In thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ------------------------
2,016 2,015 2,016 2,015
----------- ----------- ----------- -----------
Net income (loss)
attributable to Nobilis
Health Corp. $ (2,759) $ 10,943 $ (2,918) $ 6,038
Interest 744 322 2,115 1,106
Income taxes 483 256 (1,766) 862
Depreciation and
amortization 2,031 1,565 6,671 3,213
----------- ----------- ----------- -----------
EBITDA $ 499 $ 13,086 $ 4,102 $ 11,219
Non-cash compensation
expenses $ 1,722 $ 2,343 $ 5,225 $ 12,469
Change in fair value of
warrant and stock
option derivative
liabilities 133 (6,381) (1,566) (4,677)
Acquisition expenses 636 617 1,819 1,955
Bargain purchase gain -- (4,358) -- (4,358)
Non-recurring expenses 1,347 -- 3,618 --
----------- ----------- ----------- -----------
Adjusted EBITDA(1) $ 4,337 $ 5,307 $ 13,198 $ 16,608
=========== =========== =========== ===========
1 Use of Non-GAAP Financial Measures Adjusted EBITDA is defined as earnings before interest, income taxes, depreciation and amortization, non-cash compensation expenses, change in fair value of warrant and stock option derivative liabilities, acquisition expenses, bargain purchase gain and non-recurring expenses. Adjusted EBITDA should not be considered a measure of financial performance required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA is an analytical indicator used by management and the health care industry to evaluate company performance, allocate resources and measure leverage and debt service capacity. Adjusted EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with U.S. GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies. The third quarter 2015 Adjusted EBITDA of $5.3 million was previously reported as $9.7 million. Due to recent SEC guidance regarding non-GAAP disclosures, the Company elected to remove the Bargain Purchase Gain previously included in the third quarter of 2015.
Contact Information: Kolin Ozonian Vice President, Corporate Development [email protected] 713-355-8614
Source: Nobilis Health Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diana Shipping withdraws bid to acquire Genco Shipping
- Silence Therapeutics closes $201M public offering of ADSs
- CleanCore Solutions to rename itself Zone Frontier Inc. on Aug. 31
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
